Catalyst Pharmaceuticals: FIRDAPSE Cliff Deferred, Capital Allocation Concerns Remain

Catalyst Pharmaceuticals, Inc. has deferred its FIRDAPSE cliff, but capital allocation remains a concern. The company's flagship drug is facing a potential patent cliff, which could impact sales. Catalyst's capital allocation strategy has been criticized, with some questioning the decision to pursue new indications for FIRDAPSE. Despite this, the company's stock has been upgraded due to its potential for growth.